mutation as a prognosis predictor of immune checkpoint inhibitor in skin cutaneous melanoma.

There is an urgent need for appropriate biomarkers that can precisely and reliably predict immunotherapy efficacy, as immunotherapy responses can differ in skin cutaneous melanoma (SKCM) patients. In this study, univariate regression models and survival analysis were used to examine the link between calcium voltage-gated channel subunit alpha 1C () mutation status and immunotherapy outcome in SKCM patients receiving immunotherapy. Mutational landscape, immunogenicity, tumor microenvironment and pathway-enrichment analyses were also performed. The mutation group had a better prognosis, higher immunogenicity, lower endothelial cell infiltration, significant enrichment of antitumor immune response pathways and significant downregulation of protumor pathways. mutation status is anticipated to be a biomarker for predicting melanoma immunotherapy effectiveness.